The intermediate filament nestin, a neural stem-cell marker, is reported to be expressed more strongly in melanomas compared with benign melanocytic lesions, and increasingly expressed in advanced melanoma stages. However, the prognostic impact of nestin on melanoma has not been well elucidated. The aim of the present study was to evaluate the prognostic influence of nestin expression in cutaneous melanoma in comparison with standard clinico-pathologic variables. In a large series of nodular cutaneous melanoma (n ¼ 348), nestin expression was assessed by immunohistochemistry using tissue microarray (TMA) sections. For comparison, nestin staining in corresponding metastases as well as in superficial spreading melanomas and benign nevi was also examined. Nestin was expressed to varying degrees in a majority of nodular melanomas (92%), and was significantly associated with increased tumor thickness, high mitotic count, and the presence of ulceration and tumor necrosis. Also, expression was stronger in the nodular type than in superficial spreading melanomas and benign nevi, but without significant difference when compared with matched metastases from the former. Importantly, strong expression of nestin was significantly associated with reduced survival in multivariate analysis. In conclusion, increased nestin expression was associated with aggressive melanoma features, with independent prognostic impact on multivariate survival analysis when compared with clinico-pathologic factors.
Cutaneous malignant melanoma is a potentially aggressive malignancy, with limited therapeutic opportunities in advanced stages. 1 The incidence is increasing in fairly skinned populations worldwide. 2 Thus, improved understanding of tumor biology and better prognostication are required as a basis for more precise management.
Nestin is an intermediate filament protein that was first described as a marker of neural progenitor cells during development of the central nervous system. 3 In addition, expression of nestin has been detected in immature or progenitor cells in nonneural tissues, 4, 5 and nestin is found in association with injuries and repair in different tissues like the central nervous system and myocardium. 4, 5 In tumors, nestin expression is reported in malignancies of various tissues, and high levels have been correlated with aggressive features in brain tumors, 6, 7 non-small cell lung cancer, 8 breast cancer, 9 gastrointestinal stromal tumors and angiosarcoma. 10 Additionally, nestin has been suggested as a marker of tumor angiogenesis in cancers such as prostate, 11 breast, 12 and colorectal cancer. 13 In cutaneous melanoma, nestin has been reported to be increasingly expressed in more advanced stages, and present only at low levels in benign melanocytic lesions. 14, 15 To the best of our knowledge, a prognostic impact of nestin on cutaneous melanomas has been indicated only in a few studies; 16, 17 however, there has been no assessment of this factor in relation to other characteristics by multivariate analyses. Here, we find that increased nestin expression is independently associated with reduced survival in comparison with a panel of clinico-pathologic features in this series of melanomas of the nodular type.
Materials and methods

Patients
This patient series consists of consecutive cases of nodular cutaneous melanoma diagnosed at the Department of Pathology, Haukeland University Hospital (Bergen, Norway) during 1981-2008. All cases diagnosed as melanoma of the nodular type, or not otherwise specified, were reviewed by microscopy, and 457 cases were finally included. There was no known history of familial occurrence. The presence of a vertical growth phase and the lack of a radial growth phase, ie, adjacent in situ or microinvasive components, were used as inclusion criteria. Cases with minor secondary involvement of the adjacent epidermis up to three epidermal ridges were included. During this period, the sentinel node procedure was not performed. The first part of this series (1981-1997) has been previously described in detail, 18 and our material was recently expanded with cases from 1998 to 2008. In addition, 58 paired metastases (local skin, regional lymph nodes, distant) (from 1981 to 1997) were included. The median age was 68 years, 50.1% were women, and median tumor thickness was 3.6 mm (range 0.7-44.0 mm).
Complete information on patient survival with time and cause of death was available in all 457 cases. Last date of follow-up was 31 December 2008, and median follow-up time for survivors was 61.5 months (range 0-330 months). During the follow-up period, 147 patients (32%) died of malignant melanoma, and 100 (22%) died of other causes.
In addition to this series of nodular melanoma, 32 cases of benign melanocytic nevi (median age 26.6 years) and 20 consecutive cases of invasive superficial spreading melanomas 41 mm in thickness (median age 49.0 years; median thickness 1.7 mm; from the period 1981-1983) were included to examine the different categories of melanocytic lesions. Previously reported information on clinico-pathologic characteristics was included for comparison. [18] [19] [20] The Norwegian Data Inspectorate and the Regional Committee for Ethics in Research (Health Region III) (178.05) have approved this project. The study was performed in accordance with the Helsinki Declaration.
Clinico-Pathologic Variables
The following variables were recorded: date of histologic diagnosis, sex, age at diagnosis, and anatomical site of the primary tumor. The hematoxylin and eosin (H&E) stained slides were reexamined, and the following histologic features were included in this study: tumor thickness according to Breslow, 21 the level of invasion according to Clark, 22 mitotic count, 19 microscopic tumor ulceration, and tumor necrosis. 20 
Tissue Microarray
The tissue microarray (TMA) technique has been described and validated in several studies. [23] [24] [25] Three tissue cylinders from representative tumor areas identified on H&E-stained slides, generally at the suprabasal area of the primary tumors, were punched and mounted into a recipient paraffin block using a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA). The diameter of tissue cylinders was 0.6 mm in the first part of this series (cases 1981-1997), while a diameter of 1.0 mm was used in the expanded part (cases 1998-2008). Sections of the resulting TMA blocks (5 mm) were made by a standard technique.
Immunohistochemistry
The immunohistochemical staining was performed on thin TMA sections (5 mm) of paraffin-embedded archival tissue. The slides were dewaxed with xylene/ethanol before microwave antigen retrieval for 20 min in Target Retrieval Solution (DAKO S1699) (pH ¼ 6). To prevent endogenous peroxidase activity, the slides were treated with peroxidase block for 5 min. The slides were then incubated for 1 h at room temperature with a monoclonal mouse nestin antibody (10c2), catalog # sc-23927 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1:200. The staining procedure was performed using the rabbit/mouse EnVision labelled polymer method (Dako, Copenhagen, Denmark), with 3-amino-9-ethylcarbazole (AEC) peroxidase as a substrate before brief counterstaining with Dako REAL hematoxylin. Negative controls were obtained by omitting the primary antibody.
Sufficient tumor tissue was available in 348 of the primary tumors; ie, in 100 of the first 202 cases (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) , and in 248 of the 255 cases more recently included (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . Further, sufficient tissue in TMA sections was available in 44 of the 58 metastases, 17 of the 20 superficial spreading melanomas, and in 30 of the 32 melanocytic nevi.
Evaluation of Staining
In tumor cells, nestin showed cytoplasmic staining. All positive cases showed varying degrees of cytoplasmic staining. Additionally, a subset of these cases also presented a suggested filamentous and submembranous staining pattern (Figure 1 ). Tumor cell nuclei were negative in all cases. The endothelial cells were stained, even in cases without expression in tumor cells.
Immunohistochemical staining of tumor cells was recorded separately for the cytoplasmic and filamentous staining, using a semi-quantitative and subjective grading system, considering both the intensity of staining and the proportion of tumor cells showing unequivocal positive reaction. A staining index (SI) was calculated as a product of staining intensity (0-3) and area of positive tumor cell; 1 (o10%), 2 (10-50%), and 3 (450%). 26, 27 The respective SIs for the two patterns were summarized.
Statistics
Univariate analyses of time to death due to malignant melanoma were performed using the product-limit procedure (Kaplan-Meier method), and differences between categories were estimated by the log-rank test, with date of histologic diagnosis as starting point. Patients who died of causes other than melanoma were censored at the date of death. The influence of co-variates on patient survival was analyzed by the proportional hazards method, and tested by the backward stepwise likelihood ratio (lratio) test. The variables were tested by a log-log plot to determine their ability to be incorporated in multivariate models. All results were considered as significant if Pr0.05.
Results
In primary nodular melanoma, nestin was expressed in tumor cells in 319 of the 348 cases recorded (92%). The cytoplasmic staining was present in all positive cases, and in addition a filamentous like pattern was expressed in a subset of 273 cases (78% of all; 86% of positive cases). Strong expression of nestin (summarized SI 43, by lower quartile) was associated with increased tumor thickness, the presence of tumor ulceration, high mitotic count, and tumor necrosis (Table 1) . However, there was no significant correlation between nestin expression and Clark's level of invasion. Strong nestin expression was significantly associated with high mitotic count by PHH3 (Phosphohistone H3) expression (P ¼ 0.003, w 2 test). The median number of PHH3-positive mitotic figures was 31.5 per mm 2 in the group with strong nestin expression, compared with median PHH3 count 20.4 per mm 2 in the cases with weak nestin (P ¼ 0.001, Mann-Whitney test). Separate analyses of the two staining patterns gave similar results (not shown).
There was no significant difference in nestin expression in metastases when compared with 
Survival Analyses
Univariate analysis showed significantly reduced survival in cases with strong expression of nestin (summarized SI43) in the tumor cells (Figure 2) , using a cutoff point equivalent to the lower quartile. In the group of cases with strong expression, the estimated 5-year survival was 59% and 10-year survival was 45%. In contrast, 5-year and 10-year survival were 85 and 75%, respectively, in the cases with weak expression of nestin (Table 2) .
In multivariate analysis (proportional hazards method), nestin expression was included together with the histopathologic variables tumor thickness, ulceration, mitotic count, Clark's level of invasion, tumor necrosis, as well as anatomical site and gender. In the final model, all variables remained, except mitotic count and ulceration (Table 3) . Tumor thickness, Clark's level of invasion, tumor necrosis, gender, and nestin expression were all independently significant.
Discussion
In this study of cutaneous melanoma of the nodular type, strong expression of nestin was associated with markers of aggressive tumors and reduced survival by multivariate analyses. To the best of our knowledge, independent prognostic importance of nestin has not been previously shown in these tumors. By immunohistochemistry, the prognostic impact has been indicated for localized melanoma in two small studies. 16, 17 In a group of stage I-II melanomas (n ¼ 73), significantly reduced survival was found in cases with increased nestin expression in both tumor cells and endothelial cells. 16 In another study of 78 cases, there was significantly worse prognosis in localized melanoma expressing nestin. 17 The 5-year survival was 480% in nestinnegative cases of all stages. 17 These studies did not report multivariate survival analyses to compare prognostic impact of nestin in relation to other features. 16, 17 In support of these observations, nestin expression has also been found on circulating melanoma cells, and increased proportion of nestinpositive cells was related to worse prognosis. 28 The level of nestin expression has been reported to increase during tumor development, with higher levels in melanomas than in dysplastic or common nevi, and also with increased levels in metastases compared with primary tumors. 14, 15 The elevated levels in malignant compared with benign melanocytic lesions have been found statistically insignificant by others. 29 Still, nestin expression differentiated between nodal melanoma metastases and nodal melanocytic nevi, by strong expression in the former, in a recent study. 30 In our study, there was no significant difference in nestin expression between primary nodular melanomas and their matched metastases. Similar finding has been reported in smaller studies when comparing nestin in the subgroup of nodular melanoma and melanoma metastases. 31 However, nestin expression was significantly stronger in nodular melanomas when compared with small subsets of superficial melanomas and benign nevi, indicating an importance of this marker for tumor progression. This is in line with other studies. 31 The rather weak staining of nestin in benign nevi, taken together with its known expression in immature and pluripotent cells, might support the understanding of nestin as a marker of dedifferentiation during tumor evolution. 15, 32 In our study, this finding is also supported by significant associations between high nestin expression and increased tumor cell proliferation as well as tumor necrosis, both markers found in dedifferentiation and more highgrade malignant tumors.
In conclusion, increased nestin expression was associated with aggressive melanoma features and reduced survival in this series of nodular cutaneous melanoma. Nestin expression in melanoma
